About this study
The purpose of this study is to evaluate the safety of administration of unlicensed, investigational frozen (cryopreserved) cord blood (CB) units. Cord blood is blood that is taken from the umbilical cord and placenta of healthy newborn babies after childbirth. The cord blood collected from a newborn baby is called a cord blood unit. Cord blood units are stored frozen in public cord blood banks.
The United States Food and Drug Administration (FDA) considers cord blood to be a biological drug. Cord blood units that meet all FDA requirements can be licensed.
In this study the cord blood units involve transplantation of unlicensed units of cord blood. These units are considered “investigational” products.
Objectives
The primary purpose of this study is to examine the safety of administration of the unlicensed investigational NCBP HPC-CORD BLOOD products in a multi-institution setting. Therefore, the study will evaluate prospectively the incidence of serious adverse reactions as well as the incidence of all infusion related reactions after administration of the unlicensed, investigational NCBP CBU.
Eligibility overview
- Participant is receiving an allogeneic hematopoietic stem cell (HSC) transplant at St. Jude Children's Research Hospital using an unlicensed cord blood unit (CBU). Participant may be of any age and either gender.
- Participant has a medical disorder affecting the hematopoietic system that is inherited, acquired, or a result from myeloablative treatment.
- Participant is receiving HPC-CORD BLOOD product manufactured by NCBP (at least one, if the graft contains more than one units).
- Participant is not receiving licensed CB products (only).
- Participant is not receiving unlicensed CB products from other CB banks (only).
- Participant is not being transplanted at a non-US transplant center.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).